[Newsletter-5] NEWS/INFOS
May 29, 2020. >> Official news bulletin for XAV19/Bulletin officiel du XAV19...
MoreIn the News/ A la une
Pays de la Loire (ma région) –Interview vidéo d’Odile Duvaux – Coronavirus...
More[Newsletter -4] NEWS/INFOS
May 22, 2020. >> Official news bulletin for XAV19/Bulletin officiel du XAV19...
More[Newsletter -3] NEWS/INFOS
May 15, 2020. >> Official news bulletin for XAV19/Bulletin officiel du XAV19...
More[Newsletter -2] NEWS /INFOS
May 8, 2020. >> Official news bulletin for XAV19/Bulletin officiel du XAV19...
More[Alerte actualité] Anticorps XAV19
30 avril 2020 Download the press release / Télécharger le communiqué
More[Newsletter -1] NEWS / INFOS
May 1st, 2020. >> Official news bulletin for XAV19/Bulletin officiel du XAV19...
MoreIn the news / A la une
Journal des Entreprises – Coronavirus – XENOTHERA : « Nous prenons des risques entrepreneuriaux...
More
Covid-19 : Xenothera cherche les moyens de finaliser un traitement
[Article presse ] Par Frédéric Thual- La Tribune , à Nantes | 26/03/2020, 15:08 Avec...
MoreCOVID19 / XAV19 : Scientific and medical rationale
Français ci-dessous « We are convinced that our treatment will be efficient, for...
More
Interview d'Odile Duvaux, présidente de XENOTHERA dans Les Echos
[Article Presse] Par Emmanuel Guimard Publié le 20 mars 2020 à 17h14...
More
Le XAV19 de XENOTHERA, un traitement prometteur pour les cas graves de Coronavirus
[Communiqué ] Nantes , le 19 mars 2020 XENOTHERA pense détenir aujourd’hui...
More
XENOTHERA presents at Toulouse ONCOWEEK 2020
At ONCOWEEK 2020 that will take place in Toulouse on Feb. 3-5,...
More
The first patient has been injected 2 weeks ago
[ Communiqué ] Nantes, December 12th, 2019 XENOTHERA is pleased to give...
More
XENOTHERA receives approval for first in man Kidney Transplant Clinical Trial
Nantes, September 11th, 2019 – XENOTHERA announces it has received Czech Republic regulatory...
More
XENOTHERA presents at ESOT 2019
XENOTHERA will participate at ESOT 2019 that will take place...
More
XENOTHERA announces receivability of its Clinical Trial Application at the Czech Republic regulatory agency for a first in man clinical trial of LIS1 in kidney transplanted patients with dose escalation.
Nantes, June 21st, 2019 – XENOTHERA announces receivability after its submission of a Clinical...
MoreXenothera Announces Publication in European Journal of Clinical Investigation on Immunological Mechanisms Underlining Use of LIS1
Kidney graft recipients receiving anti-lymphocyte globulins of animal origin undergo unwanted immune...
More
XENOTHERA to raise Series A
XENOTHERA has started to gather investors for a Series A round of...
More
XENOTHERA sponsors the realization of a fresco for the hospital by transplanted patients
Nantes, november 2017 The fresco, more than 8 meters long, has been...
More
XENOTHERA nominated for the Ernst&Young Entrepreneur Award
Nantes, September 2017 We have been selected for the 2017 entrepreneur awards...
More
Distinction: Jean-Paul SOULILLOU awarded for its international exceptional career and contribution in transplantation
August 25th, 2016 XENOTHERA, a young start-up from Nantes, is honored to...
More